Investigates the potential therapeutic value of once-daily regimen of saquinavir, ritonavir, didanosine and lamivudine in HIV-infected patients with standard tuberculosis therapy by researchers from Barcelona, Spain. Indications showing HIV and tuberculosis to interact synergistically with each other; Prevalence of tuberculosis presenting as the most important serious opportunistic infection affecting people with HIV; Efficacy and safety of a once-daily regimen with a drug regimen combining the above stated agents.